Refactor Capital
Edit

Refactor Capital

http://www.refactor.com
Last activity: 05.02.2025
Active
Invests in categories: HealthTechCarePlatformDrugProductCryptoTechnologyDataMedtechIT
Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Portfolio
89
Mentions
24
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 89

DateNameWebsiteTotal RaisedLocation
31.12.2024Parallel B...parallel.bio$4.3MUnited Sta...
31.12.2024General Ga...gengalactic.com$8M-
31.12.2024NetworkOce...networkocean.io--
31.12.2024Adventris ...adventris.com-United Sta...
31.12.2024Vitra Labsvitra.bio-United Sta...
31.12.2024Biobot Ana...biobot.io$67.04MUnited Sta...
31.12.2024Granza Bio...granzabio.com$7M-
28.05.2024Bedrock Ma...bedrock.inc$9M-
15.03.2024301 Moved ...mymiist.com--
15.03.2024playground.ai--
Show more

Mentions in press and media 24

DateTitleDescription
06.02.2025Miist Therapeutics: Breathing New Life into Medicine with $7M FundingIn the bustling world of healthcare innovation, Miist Therapeutics stands out like a lighthouse in a storm. The Alameda, California-based company has just secured $7 million in seed funding, a financial boost that promises to propel its gro...
05.02.2025Miist Therapeutics Raises $7M to Develop Inhaled Medicines with Physics-Based ApproachWhat You Should Know: – Miist Therapeutics, a pioneering company developing inhaled medicines with a focus on rapid drug delivery raises $7M ina seed funding round led by Refactor Capital with participation from 1517 Fund, Freeflow Ventures...
22.04.2024General Galactic emerges from stealth to make methane from carbon dioxidePlenty of products benefit from tight integration, where companies design and sometimes build key components of a product in-house: Apple and its custom microprocessors and Tesla and its Superchargers are two notable examples. It’s not an e...
13.03.2024IVF uncertainty aside, startups rush to offer fertility care amid rising demandAI tools, egg freezing, surrogacy, IUI, donorship, oncofertility, genetic analysis, loans, and more In the aftermath of the Roe v. Wade overturn, U.S. fertility clinics (and patients alongside them) are battling an unlikely complication in ...
07.07.2022The Week in Agrifoodtech: Green Generation Fund raises $120m, Amazon takes Grubhub stakeThis week, Germany’s Green Generation Fund landed more capital to invest in alt-protein startups, while Israeli foodtech firm Phytolon scored funding for its natural food coloring tech. In the food delivery realm, Amazon bought a stake in G...
07.07.2022BREAKING: Fyto lands $15m to grow aquatic “superplants” for animal feed and beyondDisclosure: AFN’s parent company, AgFunder, is an investor in Fyto. US-based agtech startup Fyto has raised $15 million in Series A funding for its specialized aquatic “superplants” that can be used for animal feed, food and soil health ing...
16.12.2021BREAKING: Phytoform bags $5.7m to boost crop resilience through genome editsAgtech startup Phytoform Labs has raised a $5.7 million Seed round of funding to scale up its AI-based plant genome-editing platform. Seed-stage investor Eniac Ventures led the round. Wireframe Ventures, Fine Structure Ventures, FTW Venture...
16.12.2021Phytoform bags $5.7m to boost crop resilience through genome editsAgtech startup Phytoform Labs has raised a $5.7 million Seed round of funding to scale up its AI-based plant genome-editing platform. Seed-stage investor Eniac Ventures led the round. Wireframe Ventures, Fine Structure Ventures, FTW Venture...
14.12.2021Ophelia Raises $50M to Expand Its Novel Approach to Opioid Addiction TreatmentWhat You Should Know: – Ophelia announced its $50 million Series B funding round, led by Tiger Global to expand access to medication-assisted treatment (the CDC’s recommended first-line treatment) to more people with opioid use disorder. – ...
04.12.2020Backed by Khosla Ventures, Rubedo Life Sciences Secures $12M for Drug Discovery PlatformWhat You Should Know: – Biopharma startup Rubedo Life Sciences raises $12M to develop a broad portfolio of innovative therapies engineered to target cells for chronic age-related diseases. – Rubedo’s proprietary ALEMBIC™ drug discovery plat...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In